Skip to content
Menu

Piper Sandler Initiates Coverage On Outlook Therapeutics with Overweight Rating, Announces Price Target of $4

Benzinga Newsdesk 21 hours ago

Analyst RatingsNewsInitiationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Piper Sandler analyst David Amsellem initiates coverage on Outlook Therapeutics (NASDAQ:OTLK) with a Overweight rating and announces Price Target of $4.

Piper Sandler analyst David Amsellem initiates coverage on Outlook Therapeutics (NASDAQ:OTLK) with a Overweight rating and announces Price Target of $4.

Read at benzinga.com